Researchers assessing the effect of age on treatment found hepatitis C therapy using pegylated interferon, ribavirin and telaprevir was effective for patients above the age of 60. Data showed 73.4% of older patients achieved rapid virological response status at four weeks, compared with 73.2% of younger patients, while sustained virological response rates at 24 weeks also were comparable.

Related Summaries